The goal of the CARVYKTI® REMS is to mitigate the risks of cytokine release syndrome (CRS) and neurologic toxicities by:

• Ensuring that Hospitals and their Associated Clinics that dispense CARVYKTI® are specially certified and have on-site, immediate access to tocilizumab.

Access comprehensive information on Risk Evaluation and Mitigation Strategies for CARVYKTI®. https://carvyktirems.com